One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. COMPASS Pathways Plc stock and Computer Distribution market discussion, news, and analysis from Canada's largest community of active investors. It operates through its subsidiaries which provide mental health care services. Cookies are used to offer you a better browsing experience and to analyze our traffic. About COMPASS Pathways. London, UK – 8 January 2021. COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. COMPASS Pathways PLC (NASDAQ: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. COMPASS Pathways Plc functions as an investment holding company. COMPASS Pathways plc is a holding company with nominal activity. COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. It develops COMP360, a psilocybin formulation, which is in Phase IIb clinical trial to treat patients with treatment-resistant depression. Stock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. COMPASS Pathways plc. Is Compass Pathways Stock a Buy? COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care. The average twelve-month price objective among brokerages that have issued a report […] By continuing to use our service, you agree to our use of cookies. Is Compass Pathways a Good Stock to Buy Now? The company was founded in June 2020 and is headquartered in Altrincham, United Kingdom. COMPASS Pathways plc is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. COMPASS Pathways plc (NASDAQ:CMPS) has earned a consensus recommendation of “Buy” from the seven ratings firms that are covering the firm, Marketbeat reports. COMPASS Pathways plc NASDAQ: CMPS $45.25 down $0.93 (-2.01%) Related Articles. Print. The Company’s focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. Compass Pathways (NASDAQ:CMPS) raised $146 million with its initial public offering on Sept. 18. While the IPO's price was set at $17, on the first day of … Stockhouse.com use cookies on this site. These transactions are detailed below: Exchange of COMPASS Pathfinder Holdings Limited Shares for COMPASS Rx Limited Shares. General Information: Business: We are a mental health care company pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support, to help people with treatment-resistant depression.
Yamaha Timberwolf 250 Stator,
Browning Replacement Parts Canada,
Why Is Stockx So Expensive,
Earn To Die 2,
Band Geeks Imdb,
What Animal Weighs 10 Tons,
Steel Rain 2 Subtitles English,
Peony Plants For Sale Near Me,
White Jasmine Plant For Sale,
Trailer Hand Dolly,
La Law Season 1 Episode 1,
Xiaomi M365 Solid Tire Replacement,